407 related articles for article (PubMed ID: 28899798)
1. Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons.
Alivernini S; Galeazzi M; Peleg H; Tolusso B; Gremese E; Ferraccioli G; Naparstek Y
Autoimmun Rev; 2017 Nov; 16(11):1096-1102. PubMed ID: 28899798
[TBL] [Abstract][Full Text] [Related]
2. Synovial Immunophenotype and Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiologic Prognosis.
Orr C; Najm A; Biniecka M; McGarry T; Ng CT; Young F; Fearon U; Veale DJ
Arthritis Rheumatol; 2017 Nov; 69(11):2114-2123. PubMed ID: 28732135
[TBL] [Abstract][Full Text] [Related]
3. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
4. Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis.
Suwannalai P; Trouw LA; Toes RE; Huizinga TW
Mod Rheumatol; 2012 Feb; 22(1):15-20. PubMed ID: 21732051
[TBL] [Abstract][Full Text] [Related]
5. An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting.
van Heemst J; Trouw LA; Nogueira L; van Steenbergen HW; van der Helm-van Mil AH; Allaart CF; Serre G; Holmdahl R; Huizinga TW; Toes RE; van der Woude D
Arthritis Res Ther; 2015 Oct; 17():276. PubMed ID: 26437716
[TBL] [Abstract][Full Text] [Related]
6. Optimization of high-throughput autoantibody profiling for the discovery of novel antigenic targets in rheumatoid arthritis.
Somers K; Stinissen P; Somers V
Ann N Y Acad Sci; 2009 Sep; 1173():92-102. PubMed ID: 19758137
[TBL] [Abstract][Full Text] [Related]
7. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA.
Hecht C; Englbrecht M; Rech J; Schmidt S; Araujo E; Engelke K; Finzel S; Schett G
Ann Rheum Dis; 2015 Dec; 74(12):2151-6. PubMed ID: 25115448
[TBL] [Abstract][Full Text] [Related]
8. Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study.
van Wesemael TJ; Ajeganova S; Humphreys J; Terao C; Muhammad A; Symmons DP; MacGregor AJ; Hafström I; Trouw LA; van der Helm-van Mil AH; Huizinga TW; Mimori T; Toes RE; Matsuda F; Svensson B; Verstappen SM; van der Woude D
Arthritis Res Ther; 2016 Dec; 18(1):285. PubMed ID: 27906045
[TBL] [Abstract][Full Text] [Related]
9. Alveolar bone loss is associated with circulating anti-citrullinated protein antibody (ACPA) in patients with rheumatoid arthritis.
Gonzalez SM; Payne JB; Yu F; Thiele GM; Erickson AR; Johnson PG; Schmid MJ; Cannon GW; Kerr GS; Reimold AM; Sokolove J; Robinson WH; Mikuls TR
J Periodontol; 2015 Feb; 86(2):222-31. PubMed ID: 25299390
[TBL] [Abstract][Full Text] [Related]
10. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis.
Reynisdottir G; Karimi R; Joshua V; Olsen H; Hensvold AH; Harju A; Engström M; Grunewald J; Nyren S; Eklund A; Klareskog L; Sköld CM; Catrina AI
Arthritis Rheumatol; 2014 Jan; 66(1):31-9. PubMed ID: 24449573
[TBL] [Abstract][Full Text] [Related]
11. HLA and rheumatoid arthritis: how do they connect?
van Heemst J; van der Woude D; Huizinga TW; Toes RE
Ann Med; 2014 Aug; 46(5):304-10. PubMed ID: 24813459
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials.
Aletaha D; Alasti F; Smolen JS
Arthritis Res Ther; 2015 Aug; 17(1):229. PubMed ID: 26307354
[TBL] [Abstract][Full Text] [Related]
13. Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission.
Pelzek AJ; Grönwall C; Rosenthal P; Greenberg JD; McGeachy M; Moreland L; Rigby WFC; Silverman GJ
Arthritis Rheumatol; 2017 Jun; 69(6):1176-1186. PubMed ID: 28118534
[TBL] [Abstract][Full Text] [Related]
14. Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive.
Hiwa R; Ohmura K; Nakabo S; Terao C; Murakami K; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Hashimoto M; Furu M; Ito H; Fujii T; Mimori T
Int J Rheum Dis; 2017 Jun; 20(6):731-736. PubMed ID: 28198158
[TBL] [Abstract][Full Text] [Related]
15. What is the ability of anti-cyclic citrullinated peptide antibodies determination in synovial fluid in discriminating rheumatoid arthritis from non-rheumatoid arthritis patients? A Tunisian cross-sectional study.
Mrabet D; Laadhar L; Sahli H; Zouari B; Haouet S; Lahmar H; Makni S; Sellami S
Clin Rheumatol; 2012 Feb; 31(2):375-9. PubMed ID: 21952975
[TBL] [Abstract][Full Text] [Related]
16. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis.
Sokolove J; Bromberg R; Deane KD; Lahey LJ; Derber LA; Chandra PE; Edison JD; Gilliland WR; Tibshirani RJ; Norris JM; Holers VM; Robinson WH
PLoS One; 2012; 7(5):e35296. PubMed ID: 22662108
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort.
Nicaise-Roland P; Nogueira L; Demattei C; de Chaisemartin L; Rincheval N; Cornillet M; Grootenboer-Mignot S; Dieudé P; Dougados M; Cantagrel A; Meyer O; Serre G; Chollet-Martin S
Ann Rheum Dis; 2013 Mar; 72(3):357-62. PubMed ID: 22580581
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
19. Anti-citrullinated protein antibodies in rheumatoid arthritis: a functional role for mast cells and basophils?
Suurmond J; Schuerwegh AJ; Toes RE
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i55-8. PubMed ID: 21339220
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
